Hepatitis C virus (HCV) infection is a serious worldwide healthcare issue. Its association with various liver diseases including hepatocellular carcinoma (HCC) is well studied. However, the study on the relationship between HCV infection and the development of insulin resistance and diabetes is very limited. Current research has already elucidated some underlying mechanisms, especially on the regulation of metabolism and insulin signalling by viral proteins. More studies have emerged recently on the correlation between HCV infection-derived miRNAs and diabetes and insulin resistance. However, no studies have been carried out to directly address if these miRNAs, especially circulating miRNAs, have causal effects on the development of insulin resistance and diabetes. Here, we proposed a new perspective that circulating miRNAs can perform regulatory functions to modulate gene expression in peripheral tissues leading to insulin resistance and diabetes, rather than just a passive factor associated with these pathological processes. The detailed rationales were elaborated through comprehensive literature review and bioinformatic analyses. miR-122 was identified to be one of the most potential circulating miRNAs to cause insulin resistance. This result along with the idea about the driver function of circulating miRNAs will promote further investigations that eventually lead to the development of novel strategies to treat HCV infection-associated extrahepatic comorbidities.
| INTRODUCTION
The hepatitis C virus (HCV) is an enveloped, single-stranded positive-sense RNA virus with estimated 150-170 million people chronically infected worldwide. Although the consequences of chronic HCV infection are generally associated with liver manifestations such as hepatic fibrosis, cirrhosis, steatosis (known as non-alcoholic fatty liver disease, NAFLD) and HCC, the liver-related mortality of 350 000 individuals annually is still underestimated due to the lack of consideration of extrahepatic repercussions. Among these extrahepatic complications, a growing body of evidence has particularly shown that HCV infection is strongly associated with the dysregulation of glucose homoeostasis such as insulin resistance (IR) and type
diabetes (T2D). Studies thus far and especially a recent ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
retrospective study with 2435 patients [1] [2] [3] have confirmed the relationship between HCV infection and T2D: People infected with HCV are 4 times more likely to develop T2D; clearance of HCV with direct-acting antivirals significantly decreases HbA1c and the dependence on anti-diabetes medications; and HCV-infected patients with uncontrolled glucose are at higher risk to develop advanced liver fibrosis, HCC, and exhibit decreased sustained virologic response (SVR) to traditional interferon treatment.
It is estimated that 75%-80% of HCV patients will progress to chronic infection, the stage highly associated with the development of intrahepatic complications that subsequently lead to metabolic disorders. Mechanistic studies have revealed that HCV protein NS5A and the core protein directly inhibit microsomal triglyceride transfer protein (MTP) activity, thereby reducing very low-density lipoprotein (VLDL) assembly and inducing hepatic steatosis. In addition, HCV core protein is also associated with excessive reactive oxidative species (ROS) production via impairment of PPARc, thereby inducing oxidative stress, mitochondrial dysfunction and steatosis. Over time, accumulation of hepatic triglycerides leads to hepatic IR via decreased insulin-stimulated glycogen synthesis and enhanced hepatic gluconeogenesis; such conditions further cause peripheral IR in multiple organs through increased circulating insulin and free fatty acid levels. 4, 5 Meta-analyses have further confirmed the positive relationship between HCV and IR. 2, 6 Furthermore, nondiabetic and non-obese chronic HCV patients exhibit decreased peripheral glucose uptake and hepatic IR. 7, 8 Decreased glucose abnormalities have also been reported among HCV patients who have SVR after interferon treatment, 9, 10 further demonstrating the role of HCV in glucose metabolism. Proposed molecular mechanisms underlying this relationship include increased serum levels of pro-inflammatory cytokines TNF-a, TNFR1, TNFR2, IL-6, IL-10, decreased adiponectin and increased intramyocellular lipocalin-2. 8, [11] [12] [13] [14] [15] These factors activate an array of intracellular signalling pathways that result in increased ROS, cellular stress and metabolic dysregulation.
There are a number of investigations on the molecular mechanisms of regulation of insulin signalling by HCV infection. Insulintreated liver tissue from non-obese and non-diabetic HCV-infected patients results in increased levels of insulin receptor and insulin receptor substrate 1 (IRS-1), but showing decreased levels of IRS-1 tyrosine phosphorylation, PI3K activity and Akt phosphorylation. 16 Similarly, HCV core protein has been found to increase serine rather than tyrosine phosphorylation of IRS-1 in hepatocytes, resulting in its degradation and impaired downstream Akt signalling. 17 HCV core protein also stimulates IRS-1 serine phosphorylation via increasing mTOR levels, again resulting in decreased Akt signalling. 18 Reduced surface expression of glucose transporters GLUT1 and GLUT2 with consequential reduction in glucose uptake in HCV-infected hepatocytes has also been reported. 19 Impairment of PI3K and Akt phosphorylation by HCV has also been demonstrated by several studies to be mediated via the increased level of suppressor of cytokine signalling 3 (SOCS3), which inhibits PI3K and Akt phosphorylation and stimulates IRS-1 and IRS-2 proteasome degradation.
20-22
Additionally, increased ER stress response caused by HCV infection elevates protein phosphatase 2A (PP2A), also an inhibitor of Akt. 24 The association of specific miRNAs with certain disease states has therefore greatly accelerated the development of miRNAs into new biomarkers and/or as therapeutic targets. As miRNAs also exist in serum and other body fluids, study of extracellular and circulating miRNA profiles has become an important approach to investigate the systematic roles of miRNA in disease development.
Although the functions of circulating miRNAs remain unclear, these miRNAs have been found to be highly stable under harsh conditions including boiling, pH change, long-term storage at room temperature and multiple freeze-thaw cycles, suggesting their important biological functions. 25 More evidence has emerged to support the idea that circulating miRNAs can function like hormones to regulate gene expression in distant tissues and organs. The changes in circulating miRNA profiles have also been revealed to be correlated with various diseases including cancers, cardiovascular disorders and diabetes. [25] [26] [27] [28] [29] Based on the analysis of current knowledge regarding the relationship between HCV infection and IR, we hypothesize that circulating miRNAs post-HCV infection can target peripheral tissues and modulate their gene expression patterns, thus serving as drivers in the development of IR and T2D. Comprehensive literature review, bioinformatics and structural analyses were carried out to examine our hypothesis. The general study approach was outlined in Figure 1 .
We will first assess the overlap between circulating miRNAs from HCV infection and from T2D/IR, and then analyse the target genes of these miRNAs and their corresponding metabolic functions. In addition to the mechanisms described above on insulin signalling pathways, we will focus on the identification of metabolic effects associated with circulating miRNAs to improve our understanding of the complicated relationship between HCV infection and peripheral The importance of miRNAs in liver pathology is also reflected on many aspects. While serum miR-122 levels increase at early stage of fibrosis with high inflammation, later during the progression of fibrosis to cirrhosis, both hepatic and serum levels of miR-122 are decreased by a large cohort study with 84 liver biopsies and 167 serum samples from chronic hepatitis C patients. 36 This is largely due to the loss of hepatocytes, which is also consistent with the inverse relationship between hepatic miR-122 and liver injuries under various conditions. 37-39 miR-122 is the most abundant miRNA in liver. 40 It is also a good biomarker for liver damage correlated with alanine aminotransferase (ALT) and aspartate transaminase (AST) activities in HCV mono-infection and HIV/HCV con-infection conditions. 41, 42 In addition, the increase in circulating miR-122 is greater in HIV/HCV co-infection than HIV mono-infection 43 ; miR-122 is also correlated with liver injury and necroinflammation (eg IL-6) caused by HIV and HIV/HCV infections. 42, 44 Based on these important findings of miR-122 in viral infection-induced liver diseases, we will focus on miR-122 in this study to discuss its role in linking HCV infection with extrahepatic comorbidities.
| Immune response
Specific changes of miRNAs with infection have been found to impact host immune response. miR-130a expression was increased in infected hepatocytes, and liver biopsy identified a target as the antiviral protein interferon-induced transmembrane protein 1 (IFITM1); subsequent exposure to anti-miR-130a increased IFITM1
expression. 45 HCV infection has also been reported to activate miR- Overexpression of miR-196 was therefore proposed as a potential therapeutic strategy to protect against oxidative stress and HCV infection. 50 A similar mechanism was identified in hepatitis B virus infection, wherein miR-143 induced hepatocarcinoma metastasis via NF-jB signalling and fibronectin repression, thus the down-regulation of miR-143 became an effective strategy to control HBV-related liver cancer progression. 51 
| Metabolic effects
Regulation of metabolism is another key function of miRNAs from HCV infection. miR-27a was found to regulate lipid metabolism via targeting transcription factor RXRa and the lipid transporter ATPbinding cassette subfamily A member 1. miR-27a also repressed several lipid metabolism-related genes (encoding SREB, PPAR and Apo family proteins) which are essential for the production of infectious viral particles. Repression of miR-27a was conversely found to increase hepatocyte lipid content and viral replication and infectivity. Interestingly, miR-27a has been found to be preferentially up-regulated during HCV infection, providing a survival mechanism by which the virus can maintain a low viral load, evade host immune surveillance, establish chronic infection and secondarily promote hepatic steatosis. 52 A similar study on miR-122 also demonstrated the importance of metabolic effects of miRNAs.
Depletion of hepatocyte miR-122 by locked nucleic acid anti-miR-122 in non-human primates generated a dose-dependent decrease in plasma cholesterol. 53 These findings along with other identified miRNAs can all target insulin signalling (eg PI3K/Akt), further demonstrating a critical role of miRNAs in associating HCV infection with the development of systemic extrahepatic complications via metabolic effects.
| Circulating miRNAs derived from HCV infection
In addition to intracellular miRNAs, extracellular circulating miRNAs have been associated with the development and progression of various diseases (eg cancer and cardiovascular disease). To better understand the linkage between HCV infection and peripheral IR and diabetes, we seek to analyse miRNAs and their target mRNAs in these 2 disease conditions. Circulating miRNA profiling of newly diagnosed T2D patients and T2D-susceptible individuals with normal glucose tolerance consistently finds miR-34a to be significantly upregulated. 54 A separate study reports miR-134 to be down-regulated in omental adipocyte samples from T2D patients, 55 and miRNA profiling of streptozotocin-induced diabetic mice reveals miR-134 to be up-regulated specifically in mitochondria of liver samples. 56 Interestingly, a few of these miRNAs in T2D/IR have also been detected in circulating miRNA profiles of HCV-infected individuals (Table 2) (Table 1) . differentially expressed in all tissues, to analyse which targets are differentially expressed in which peripheral tissues. 62 As shown in 
| miR-122 target genes regulate IR and T2D in skeletal muscle and adipose tissue
To further evaluate miR-122 targets that play important roles in clinical IR tissues, we analysed the relationship between miR-122 targets and the down-regulated genes (≥2-fold decrease) in human IR tissues using the microarray data from 4 studies in Gene Expression Omnibus (GEO) 63 ; 2 assessing skeletal muscle and 2 assessing adipose tissue (Table 4) Table 4 in both skeletal muscle and adipose tissue have been previously experimentally verified as well.
F I G U R E 3 miR-122 targets IR-relevant genes differentially expressed in adipose, skeletal muscle and pancreas. Distribution of miR-122 predicted targets (511 input genes) differentially expressed in various tissues and compartments was analysed via GeneAnalytics LifeMap Tool, including adipose (22), skeletal muscle (8) and pancreas (27) 
| MOLECULAR MECHANISMS TO SUPPORT THE FUNCTION OF CIRCULATING MIR-122 IN TARGET CE LLS
Whether circulating miRNAs are functionally significant or simply byproducts of cell activity is still debatable; however, strong evidence for both sides of this relationship has emerged. 69 Circulating miRNAs can be co-purified with microvesicles and exosomes, 70 Figure 4C ). This confirmation may be ideal as it exposes only bases that are required for mRNA targeting.
Studies have also shown that miRNAs containing high percentage of adenine exhibit reduced mRNA targeting activity. It was also found that AGO2-associated miRNAs contain less adenine nucleotides at their 3 0 -end when compared to miRNAs extracted from the whole cell. 87 Consistent with this rule, we noticed that miR-122 contains more G (40.91%) and U (36.36%) bases than A bases (18.18%) in the regions outside of the 3 0 -end, further supporting miR-122 as a strong candidate for functioning through AGO2 ( Figure 4B ). cles. 91 The discovery of specific miRNA 3 0 -end sequence motifs (EXOmotifs) favours the loading into exosomes through the interaction with nuclear ribonucleoprotein A2B1 (hnRNPA2B1). 92 However, miR-122 does not meet these criteria with 3 0 -end guanine and the lack of identified EXOmotifs. Therefore, other unknown mechanism (s) may be involved in the loading of miR-122 into exosomes. As mentioned above, miR-122 may simply form a complex with AGO2
instead of exosome packaging for efficient circulation. miRNA uptake or induce an endocytosis process. However, there is research reporting that AGO2 is localized on rough ER membrane and can bind to miRNA to cause its release from ER to target cellular mRNA. 93 In addition, another study also identified the association of AGO2 with plasma membrane in NK cells, 94 suggesting that AGO2 might have a potential membrane function to assist miR-122 uptake by target cells. AGO2 might also be able to interact with other endocytosis complex protein(s) to facilitate miR-122 uptake. This is an untested but significant topic that warrants further investigation. Predicted miR-122 targets were compared with down-regulated genes (≥2 fold, P < .05) in skeletal muscle and adipose tissue samples in 4 reported microarray studies using Gene Expression Omnibus (GEO). Targets that are more likely associated (direct or indirect) with IR-relevant phenotypes were determined using VarElect (phenotype query: insulin resistance, glucose intolerance, lipid metabolism, type 2 diabetes, glucose metabolism, lipid storage and inflammation).
| CONCLUSION S
a Experimentally verified targets (DIANA-microT-CDS). Lists of all overlapped genes from above 5 comparisons are available in Data S3.
F I G U R E 5
Working model for hepatic and circulating miR-122 to mediate IR and diabetes associated with Hepatitis C virus (HCV) infection. Key metabolic and cell signalling pathways impacted are illustrated, summarizing the findings from literature review and bioinformatics analyses in this study miR-122 in extrahepatic tissues. Our viewpoint regarding the "hormonal" function of miR-122 is supported by a recent study that obese mice adipose tissue macrophage-derived exosome can cause systemic insulin resistance and glucose intolerance in lean mice, wherein miR-155 is the causative factor. 95 This study also suggests that other miRNAs identified in Table 2 may exert functions in the association of HCV infection with IR and diabetes. Interestingly, miR-155 is exactly on the list as one candidate in Table 2 .
miRNAs identified from this analytical review will be experimentally verified as our ongoing research project. In summary, the information and ideas from this review shed new light on our understanding about the development of IR and diabetes associated with HCV infection from a different angle through non-coding RNA, thus providing us a new strategy for drug development to treat HCV infection-associated extrahepatic diseases and complications.
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